Pharmacological treatments for fragile X syndrome based on synaptic dysfunction.
Sign Up to like & getrecommendations! Published in 2019 at "Current pharmaceutical design"
DOI: 10.2174/1381612825666191102165206
Abstract: BACKGROUND Fragile X syndrome (FXS) is the most common form of monogenic hereditary cognitive impairment, including intellectual disability, autism, hyperactivity and epilepsy. METHODS This article reviews the literature pertaining to the role of synaptic dysfunction… read more here.
Keywords: fxs; pharmacological treatments; fragile syndrome; dysfunction ... See more keywords